BlinkLab Partners With Erasmus MC to Expand Into Therapy Evaluation for APDS
BlinkLab partners with Erasmus MC to expand into therapy evaluation for neurodevelopmental conditions
BlinkLab Limited (ASX: BB1) has entered an academic research agreement with Erasmus University Medical Centre (Erasmus MC) in Rotterdam, the largest university medical centre in the Netherlands, to study treatment-related changes in patients with Activated PI3K Delta Syndrome (APDS). The announcement, dated 19 May 2026, marks a strategic expansion of BlinkLab’s neurometric platform beyond diagnostics into therapy evaluation, treatment monitoring, and future digital endpoints for pharmaceutical and interventional studies.
APDS is a rare inborn error of immunity associated with neurodevelopmental and behavioural symptoms, including autism. BlinkLab’s smartphone-based neurometric technology will be used to provide objective measures of patient responses to treatment, an outcome the company states has not been possible previously.
When big ASX news breaks, our subscribers know first
What is APDS — and why does it matter for BlinkLab investors?
Understanding Activated PI3K Delta Syndrome
APDS is a rare immune disorder caused by mutations that hyperactivate the PI3K delta pathway, a signalling route involved in immune cell regulation. Beyond its immunological profile, APDS is increasingly recognised as being associated with neurodevelopmental and behavioural symptoms, including autism-linked traits. To date, these manifestations have rarely been studied using objective, scalable tools capable of repeated deployment over time.
The study evaluates behavioural and neurodevelopmental function in patients before and during treatment with a selective PI3Kδ inhibitor, a pathway-targeted therapy for APDS. The FDA has already approved a selective PI3Kδ inhibitor for APDS1, confirming that targeted therapies are reaching this rare, biologically defined patient population. Separately, recent FDA action involving leucovorin in cerebral folate deficiency with autistic features illustrates the growing regulatory attention being directed toward conditions that sit at the intersection of biology, neurodevelopment, and behaviour.
BlinkLab’s reflex-based and broader sensorimotor neurometric platform is smartphone-based, remote, and repeatable. This enables longitudinal measurement of patient responses to treatment across neurodevelopmental domains that have historically been difficult to quantify with objective, scalable tools. The company believes this positions its technology to support pharmaceutical companies and academic groups seeking rigorous, remote endpoints in clinical development programmes.
From diagnostics to therapy evaluation — a strategic platform expansion
Why this partnership extends BlinkLab’s commercial runway
The Erasmus MC collaboration formalises a strategic direction BlinkLab has described since listing, expanding a platform that was built with both diagnostic and therapeutic applications in mind. The partnership broadens the company’s addressable opportunity across several use case areas:
- Diagnostic assessment (existing core — autism and ADHD)
- Therapy evaluation
- Treatment monitoring
- Digital endpoints for pharmaceutical and interventional studies
- Quantifying treatment response longitudinally
- Identifying patient subgroups in biologically defined neurodevelopmental disorders
The company’s primary regulatory focus remains its autism and ADHD diagnostic programmes. This collaboration is additive to that strategy, not a redirection of it.
The Erasmus MC and Princeton University connection
The partnership is grounded in an established scientific relationship. Managing Director and CEO Dr Henk-Jan Boele notes that he and Principal Investigator Dr Aleksandra Badura have worked together successfully over many years through projects connected to Erasmus MC and Princeton University, anchoring the agreement in proven collaboration rather than a purely commercial arrangement.
Dr Henk-Jan Boele, Managing Director and CEO, BlinkLab
“This is a very exciting step for BlinkLab because it will further unlock the full potential of our technology. From the start, our ambition has been to build a platform that is useful not only for diagnostic support, but also for formalising objective measurement in therapeutic and treatment studies.”
Dr Aleksandra Badura, Principal Investigator, Erasmus MC
“Combining our clinical and translational expertise with BlinkLab’s scalable neurometric technology opens up a promising way to study treatment effects more objectively over time.”
The next major ASX story will hit our subscribers first
BlinkLab at a glance
| Category | Detail |
|---|---|
| ASX Code | BB1 |
| Founded by | Neuroscientists at Princeton University |
| Core technology | Smartphone-based, AI/ML-powered neurometric diagnostic platform |
| Lead product | BlinkLab Dx 1 — autism diagnostic aid for clinicians |
| New collaboration | Erasmus MC, Rotterdam — APDS therapy evaluation study |
| Platform applications | Diagnostics, therapy evaluation, treatment monitoring, digital endpoints |
| Primary regulatory focus | Autism and ADHD diagnostic programmes |
The Erasmus MC partnership represents a meaningful expansion of BlinkLab’s addressable opportunity, extending the platform’s application from diagnostic support into real-world therapeutic research. As more targeted therapies emerge for neurodevelopmental conditions and related syndromes, the company is positioning its technology to support pharmaceutical companies and academic groups seeking objective, remote, and repeatable endpoints for clinical development programmes.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers staying ahead of market-moving announcements the moment they drop. Click the “Free Alerts” button at Big News Blast to get started today.